Home›Trial›NCT06229210
NCT06229210Phase 3RECRUITING

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

Study Summary

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

Conditions
SchizophreniaBipolar DisorderAutism Spectrum Disorder
Interventions / Drugs
Lumateperone
View on ClinicalTrials.gov ↗
Sponsor
ITCI
Intra-Cellular Therapies
Neuroscience
D38/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorIntra-Cellular Therapies, Inc.
Data Retrieved2026-04-11 04:18:13.264722+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 500 participants
Sponsor Catalyst Profile

Intra-Cellular Therapies (ITCI) is the sponsoring company for this trial. BiotechSign currently grades this company D (38/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ITCI Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.